Balyasny Asset Management
LEGN icon

Balyasny Asset Management’s Legend Biotech LEGN Stock Holding History

Balyasny Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Buy
+210,996
New +$5.69M 0.01% 1288
2026
Q1 		– Sell
-343,785
Closed -$7.47M – 3229
2025
Q4 		$7.47M Buy
343,785
+308,618
+878% +$8.84M 0.01% 1176
2025
Q3 		$1.15M Sell
35,167
-912,466
-96% -$33.7M ﹤0.01% 2058
2025
Q2 		$33.6M Buy
947,633
+746,642
+371% +$24.2M 0.05% 456
2025
Q1 		$6.82M Sell
200,991
-898,534
-82% -$32.2M 0.01% 1110
2024
Q4 		$35.8M Buy
1,099,525
+418,351
+61% +$17.3M 0.05% 436
2024
Q3 		$33.2M Buy
681,174
+229,209
+51% +$12.2M 0.05% 441
2024
Q2 		$20M Buy
+451,965
New +$20.8M 0.04% 606
2022
Q4 		– Sell
-16,000
Closed -$653K – 3022
2022
Q3 		$653K Buy
16,000
+10,485
+190% +$492K ﹤0.01% 1958
2022
Q2 		$303K Buy
+5,515
New +$233K ﹤0.01% 2099

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Balyasny Asset Management's LEGN Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Legend Biotech (LEGN) in Q2 2026: 210,996 shares worth $6.09M. The stake represents 0.01% of the portfolio and ranks #1288 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in LEGN as recently as Q4 2025.

Balyasny Asset Management first reported a position in LEGN in Q2 2022 and has held it in 10 quarters since. The position peaked at $35.8M in Q4 2024. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Balyasny Asset Management held 210,996 shares of Legend Biotech worth $6.09M as of Q2 2026.
  • Legend Biotech was a new Balyasny Asset Management position in Q2 2026.
  • Legend Biotech made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1288 holding.
  • Balyasny Asset Management first reported a position in Legend Biotech in Q2 2022 and has held it in 10 quarters since.
  • Balyasny Asset Management's Legend Biotech position peaked at $35.8M in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.